## Resident Doctors Suspend Strike Action Following Eleventh-Hour Government Proposal

Resident doctors in England have called off a planned strike that was set to begin on Monday morning, after the government stepped forward with a new offer just hours before action was due to commence.

The British Medical Association (BMA) confirmed it had received a fresh proposal from the government and announced it would be presenting the offer to its members for a vote, prompting the cancellation of what would have been the sixteenth walkout in this prolonged pay dispute.

### What Was Planned — And What Changed

The strike had been scheduled to run from 07:00 BST on Monday 15 June through to 06:59 on Friday 19 June. Negotiations between the two sides had been ongoing for several days, with talks continuing into Saturday — just hours before the decision to stand down was made.

Health Secretary James Murray described the new proposal as "a chance to draw a line under the damaging disputes of recent years." The BMA, for its part, stated it had held up its "end of the bargain" once the government demonstrated a willingness to shift its stance.

### What the New Offer Includes

While government sources confirmed there would be no additional funding for pay increases in the current financial year, the revised offer reportedly includes:

- **Accelerated pay scale increases** beginning next year
- **4,500 additional training places** for newly qualified doctors
- **Coverage of doctors' exam fees**, reducing out-of-pocket expenses

These concessions represent a notable step forward from a previous offer made in April, which the BMA had rejected despite it including more training positions and faster career progression pathways.

### The Broader Pay Dispute

Resident doctors — formerly referred to as junior doctors — have received cumulative pay rises of 33% over the past four years, including a 3.5% increase this year. Starting salaries now sit just above £40,000, while the most senior resident doctors earn £76,500 in basic pay, with additional earnings available for unsociable hours and overtime.

However, the BMA maintains that when adjusted for inflation, doctors are still earning approximately 20% less in real terms than they were in 2008. This argument has underpinned the union's ongoing campaign for a more substantial pay restoration.

The union has been engaged in a series of strikes across England since 2023, with the most recent being a six-day walkout in April. That action followed the BMA's rejection of an offer it deemed insufficient to address the long-standing pay gap.

### Patient Impact Still Being Felt

Despite the strike being called off, the disruption was not entirely avoided. NHS England indicated that while 95% of scheduled operations and appointments were expected to proceed as planned, thousands of procedures had already been postponed in anticipation of the walkout. Restoring those appointments to their original schedule is expected to present a significant logistical challenge for NHS trusts.

### Reactions From Key Figures

Health Secretary James Murray welcomed the development, stating: "It is a positive and welcome development — especially for patients — that the BMA have called off these unnecessary strikes. The country simply cannot afford to increase the pay offer for this year."

Dr Jack Fletcher, Chairman of the BMA's Resident Doctors Committee, acknowledged the progress while expressing frustration at the timing: "This should not have been left to the last moment, but we hold up our end of the bargain when the government shifts its position."

Sir Ciarán Devane, Chief Executive of the NHS Alliance, described the suspension as "a vital chance to reset the conversation," urging both parties to work toward a "fair, sustainable agreement."

### A Dispute With Deep Roots

The origins of the latest escalation trace back to a meeting in May, during which Health Secretary Murray reportedly signalled he was unwilling to negotiate on pay, describing the BMA's demands as "unrealistic and unaffordable." The union had drawn comparisons between his position and that of his predecessor, former Health Secretary Wes Streeting.

With the new offer now in the hands of BMA members, the coming weeks will be critical in determining whether this long-running dispute can finally be brought to a close.

Resident doctors in England cancel their planned strike after the government tables a last-minute offer including faster pay rises and 4,500 new training places

Resident Doctors Call Off Strike After New Government Offer

40c89fc0-675f-11f1-8e1d-bbbb1017d210.jpg

Resident Doctors Call Off Strike After Last-Minute Government Offer

## The NHS Diagnostic Backlog Has a Clear Cause — And It's Not Laziness

As NHS diagnostic waiting lists continue to stretch to record lengths, a familiar narrative has begun to emerge from some quarters: that the solution lies in squeezing more efficiency out of existing staff, offering financial incentives, and streamlining patient communication. But according to Richard Evans, CEO of the Society and College of Radiographers, this framing dangerously misses the point — and risks unfairly maligning a workforce already operating beyond its limits.

## Radiographers Are Already Working at Maximum Capacity

The numbers tell a striking story. In March 2026, NHS radiographers — the professionals responsible for conducting diagnostic imaging tests — performed 2.07 million scans in a single month, the highest monthly total ever recorded. Far from underperforming, these healthcare workers are consistently pushing output to unprecedented levels.

What makes this achievement even more remarkable is the conditions under which it is happening. The average vacancy rate across radiography departments has now reached 15%, with some individual departments facing even steeper shortfalls. Staff are routinely working overtime in an effort to keep pace with patient demand. There are, bluntly put, no additional safe working hours left to give.

### Suggesting Financial Incentives Misreads the Crisis

When industry voices suggest that better use of existing capacity or financial incentives could solve the problem, it implies that radiographers are either not working hard enough or could be motivated to work longer hours for extra pay. Evans firmly rejects this characterisation, describing it as a naive misrepresentation of the real situation on the ground.

## A Workforce Plan That Has Yet to Materialise

Part of the problem lies in the current political landscape. Government focus has been heavily directed toward abolishing NHS England and restructuring regional integrated care boards. A significant consequence of this reorganisation has been a wave of recruitment freezes across NHS trusts throughout the country.

This has created a deeply paradoxical situation: radiography graduates are completing their degrees and struggling to secure employment, even as hospitals face chronic and well-documented staff shortages. Vacant posts are going unfilled not because suitable candidates don't exist, but because trusts have paused hiring.

### Burnout Is Driving Experienced Staff Out of the NHS

The human cost of this crisis is becoming increasingly visible. Members of the Society and College of Radiographers report widespread burnout, with a growing number of experienced professionals choosing to leave the NHS entirely rather than continue working under unsustainable conditions. Once these workers are lost, replacing their expertise is neither quick nor cheap.

## What Needs to Happen Next

Evans is unequivocal in his message: without a credible and fully funded government workforce strategy that prioritises the recruitment and retention of radiographers, NHS diagnostic waiting lists will continue to grow — and patients will bear the consequences.

Existing capacity has been stretched to its absolute limit. The path forward is not about incentivising staff to work harder; it is about ensuring there are enough trained professionals to meet the scale of patient need. Until that investment is made, the backlog will only deepen.

NHS radiographers are setting records for tests performed, yet a 15% vacancy rate and recruitment freezes mean diagnostic waiting lists keep growing.

Why NHS Diagnostic Waiting Lists Keep Getting Longer

large_3640.jpg

medium_3640.jpg

small_3640.jpg

thumbnail_3640.jpg

3640.jpg

The Real Reason NHS Diagnostic Waiting Lists Keep Growing

## When Grandmothers Rule the Pitch

At most sporting events, officials check credentials to keep ineligible players *out*. At the Grannies International Football Tournament — better known as GIFT — they check passports for an entirely different reason: to make sure nobody is too *young* to play.

"We don't want to see underage players," one match official explained with complete seriousness, flipping through a stack of passports before a recent match in Tzaneen, South Africa.

The minimum age to compete? Fifty years old. And that rule is non-negotiable.

## A Tournament Unlike Any Other

Held in the small South African farming town of Tzaneen, GIFT brings together teams of women aged 50 and above from across the globe. Vuvuzelas blast through the humid air, crowds pack the stands, and grandmothers — gogos, nanas, vovos, and mamis — take to the field with fierce competitive intent.

The second edition of the tournament, held in early April 2025, drew teams from seven countries, including the United States, France, Togo, Kenya, Mozambique, Zambia, and a host of South African squads. For four intense days, the stadium in the Nkowankowa township became the center of the women's football universe — at least for the 50-and-over crowd.

And what a crowd it was. The stands filled with fellow grandmothers cheering passionately for their favorite teams. Some brought knitting. Some dozed briefly between matches. All of them erupted with joy when their side found the net.

## Stars of the Field — At 72, 78, and Beyond

On the pitch, the action was anything but slow. In a match between the United States and Togo, American forward Pam Woodworth, 72, burst past three defenders — white ponytail flying — and delivered a precise pass to center forward Sue "Clip" Clippinger, 78, who buried a hard, high shot into the corner of the net.

"Goooooaaaalll!" roared commentator Ishmael Maluleke, a former South African professional player. "What a performance from Granny #4 of the USA. She is the USA's Messi!"

Clippinger, who plays for the New England Breakers, says the experience has only sharpened her game. "I've gotten better at this than when I was 40," she said with a grin.

## A Dream Born in a Small Farming Town

The story behind GIFT is as remarkable as the tournament itself. It begins in 2007, when a Tzaneen radio host and philanthropist named Beka Ntsanwisi — affectionately called Mama Beka — decided to organize a soccer league for older women in her community. Her goals were simple: improve health outcomes and give women a reason to move their bodies and connect with one another.

The early days were not without obstacles. One of the original players, Rossina Mathye, now 84, recalled quietly wrapping a long skirt over her soccer shorts before leaving home for practice. "You see, in our culture … trousers are for men," she explained. If the women wanted to play, the men in the community simply couldn't know what was happening.

Despite those challenges, the league took root and flourished. Inspired by South Africa's beloved national teams — Bafana Bafana (Boys Boys) and Banyana Banyana (Girls Girls) — the players named themselves **Vakhegula Vakhegula**, which translates to "Grandmothers Grandmothers" in the local Tsonga language.

## From Local League to International Stage

By the time South Africa hosted the FIFA World Cup in 2010, the Vakhegula Vakhegula had become minor local celebrities. Shortly after the tournament concluded, an all-star squad of the grannies boarded a flight to Boston, Massachusetts, after American women who had seen footage of them playing extended an invitation to compete in a tournament for older players.

That trip planted a seed in Ntsanwisi's mind. If Boston could host something like that, she reasoned, why not Tzaneen? Never mind that the town sits a five-hour drive from the nearest major international airport in Johannesburg, surrounded by groves of orange and avocado trees. Ntsanwisi had already built a soccer league from nothing. Hosting a world championship felt like the logical next step.

"One day," she promised herself, "I'm going to host the World Cup." The grannies' World Cup, that is.

It took a decade of planning, but in 2023, the inaugural GIFT kicked off at the soccer stadium near Ntsanwisi's childhood home, welcoming teams from six nations. The 2025 edition expanded even further, with Zambia among the new additions — though their team had to hitchhike to the stadium after their bus broke down in southern Zimbabwe, some 200 miles away, during the opening ceremony.

## Making Up for Lost Time

For many of the women competing in GIFT, the tournament represents something far deeper than a sporting event. A large number of them grew up in communities where soccer was considered a male pursuit. As the years passed, personal ambitions gave way to caregiving — for spouses, children, and eventually grandchildren.

Now, on the grass of a stadium in rural South Africa, they are finally getting their moment.

Rossina Mathye, who has ten grandchildren and is also a great-grandmother, no longer plays due to sore knees. But she hasn't left the game behind. "Now I sit and watch," she said warmly. "Now I'm one of their biggest supporters."

The stadium, the roaring crowd, the FIFA anthem crackling over the speakers — none of it is wasted on these women. They know exactly how long they waited for this.

And they have absolutely no intention of leaving the pitch early.

Meet the women over 50 competing at the Grannies International Football Tournament in South Africa — a global soccer event where age is just the entry fee.

Grannies International Football Tournament: Soccer Over 50

large_jpeg

medium_jpeg

small_jpeg

thumbnail_jpeg

jpeg

The Granny World Cup: Meet the Soccer Players Who Are Too Old to Be Stopped

## Toxic Chemicals Detected in US Breast Milk Samples

A new peer-reviewed study has uncovered deeply troubling levels of hormone-disrupting chemicals in breast milk samples collected from mothers in Seattle. The findings, which identified substances including BPA, BPS, melamine, cyanuric acid, and triclosan, have prompted serious concern among health experts who describe the situation as a "widespread, systemic problem" driven by unchecked chemical use across consumer industries.

### What the Research Found

Researchers analyzed 50 breast milk samples and discovered that approximately 92% contained at least one of the anti-microbials or plasticizers they were testing for. BPA was detected in 74% of samples, while BPS showed up in 78%. Triclosan was present in 62% of samples, and melamine — one of the first times this compound has been identified alongside multiple other endocrine-disrupting chemicals in breast milk — was found in a striking 92% of samples.

These same samples had previously tested positive for elevated levels of PFAS "forever chemicals" and flame retardants, both of which are also known endocrine disruptors, compounding the overall concern.

### Why This Matters for Infant Health

The stakes are particularly high because breast milk is the primary source of nutrition for newborns — a group that is especially vulnerable to chemical exposure. Infants undergo rapid developmental changes that are largely governed by the endocrine system, making any interference with hormonal function potentially serious.

"This pertains to the most vulnerable group when it comes to health effects — infants and children — who are undergoing rapid stages of development that are orchestrated by the endocrine system," said Ryan Babadi, a lead author of the study and senior scientist at the nonprofit Toxic Free Future.

Research has linked BPA to impaired neurodevelopment, asthma, and obesity, while BPS has been associated with lower body weight in young children. Triclosan, commonly added to personal care products as an anti-microbial agent, adds yet another layer of hormonal risk. Though research on the combined effects of these chemical mixtures remains limited, early studies suggest links to lower birth weight and reduced size in newborns.

### Breastfeeding Still Recommended

Despite the alarming findings, researchers are careful to emphasize that breastfeeding remains the healthiest option for infants when feasible. Babadi noted that many of the same chemicals are also present in infant formula, meaning switching away from breast milk does not necessarily eliminate the exposure risk. The issue, experts stress, is not breastfeeding itself — it is the pervasive presence of these chemicals throughout the consumer goods environment.

"People cannot shop their way out of this," Babadi said, acknowledging that while reducing plastic use and making mindful purchasing decisions can help, the chemicals are so deeply embedded in everyday products that individual choices alone are insufficient.

### A Systemic Failure of Regulation

The study points to a broader regulatory failure as a root cause of the contamination. Endocrine-disrupting chemicals are routinely incorporated into a wide range of everyday products. Plasticizers like melamine, BPA, and BPS are used in food packaging, plastics manufacturing, and UV protection applications. Anti-microbials like triclosan appear in personal care items including soaps and toothpastes.

While some chemical concentrations in the samples fell below the World Health Organization's tolerable daily intake thresholds, the study's authors note that prior research has shown harm can occur even at lower exposure levels — raising questions about whether current safety benchmarks are adequate.

The researchers acknowledge the study's limitations, including its relatively small sample size and a participant pool that skewed toward higher-income and more educated mothers, which may not fully reflect national exposure patterns.

### Political Climate Threatens Progress

The timing of these findings is particularly significant. The current administration's Environmental Protection Agency has moved to roll back restrictions on numerous toxic substances in consumer products and drinking water. Simultaneously, Congress is reportedly considering weakening the country's foundational laws governing chemical safety.

Babadi warned that such policy reversals would only worsen the situation. "That would make the exposures we see in this paper worse, and it would worsen the health of not only children but adults, workers and communities," he said.

The study's authors are calling for stronger chemical safety protections rather than the deregulation currently being pursued at the federal level, arguing that the data clearly demonstrates the urgent need for more robust oversight of hormone-disrupting substances across all consumer industries.

A new study finds alarming levels of BPA, triclosan, and melamine in Seattle mothers' breast milk, raising urgent concerns about infant health and chemical safe

Hormone-Disrupting Chemicals Found in US Breast Milk

large_5021.jpg

medium_5021.jpg

small_5021.jpg

thumbnail_5021.jpg

5021.jpg

Toxic Chemicals Found in Breast Milk Samples Raise Serious Health Alarms

## The Hidden Role of Telehealth Companies in Obesity Drug Coverage

When most people think about telehealth companies offering weight loss support, they imagine a helpful service designed to maximize patient success. The reality, however, is far more complicated — and for many patients, far more frustrating.

While telehealth providers do offer lifestyle coaching and clinical guidance for people using GLP-1 medications like Wegovy and Zepbound, they are increasingly being hired by employers with a very different priority in mind: controlling how much money gets spent on these expensive drugs.

## One Patient's Struggle to Access a Prescribed Medication

David Davis, a 57-year-old power plant worker from Aptos, California, knows this frustration all too well. His primary care physician had already written him a Zepbound prescription back in December to address his obstructive sleep apnea — a condition that was leaving him completely drained every single morning.

Before he could even fill that prescription, his employer changed the rules. He was now required to obtain a new prescription exclusively through Vida Health, an online telehealth platform his company described as a "cardiometabolic weight loss solution" and presented as a benefit to employees.

Davis complied. He completed new bloodwork, answered detailed health questionnaires, and attended video consultations with a Vida Health nurse. The nurse acknowledged he was a suitable candidate for Zepbound — but insisted he first try naltrexone and bupropion, medications primarily used to treat alcohol dependency, opioid use disorder, and depression. Neither drug carries approval for treating obstructive sleep apnea.

"I thought, 'All right, I'll jump through their hoops,'" Davis said. "The more they wanted, the more frustrated I would get."

When Davis reached out to his insurer's patient advocate to question the requirement, the advocate expressed surprise — saying it wasn't an established rule at all. Exhausted by the process, Davis ultimately gave up on getting his insurance to cover the medication and began paying out of pocket for a compounded version through an online pharmacy.

Vida Health declined to address questions about Davis' specific case, even after he agreed to waive his patient privacy rights. In a general statement, the company said its providers follow clinical eligibility criteria and plan sponsors' coverage policies, and that delivering "personalized, clinically appropriate care" remains its top priority.

Blue Cross and Blue Shield of Texas, which administers Davis' insurance plan, issued a statement affirming its commitment to safe and appropriate care, but declined to comment on the specifics of his situation.

## A Booming Industry Built Around Cost Control

Telehealth companies offering metabolic health services aren't new. According to Jayne Hornung, chief clinical officer at MMIT — a pharmaceutical market data firm — these platforms originally focused on Type 2 diabetes prevention and management. The explosive growth of GLP-1 obesity drugs, however, created an enormous new market opportunity.

"They've seen this opportunity in the larger market with the GLP-1s and all the wraparound services that they could provide," Hornung explains. "And it's just exploded."

The numbers reflect that growth. Omada Health, one of the leading players in this space, recently reported a 51% membership increase over the past year, surpassing one million members. The company also disclosed that it had supported more than 150,000 members on GLP-1 medications by the end of 2024, up from roughly 50,000 the year before.

Omada's president, Wei-Li Shao, pushes back on characterizations of his company as a barrier to medication access. "Omada is neither a gatekeeper of GLP-1s nor are we a vending machine," he says, describing the platform as providing evidence-based care with providers who understand individual plan coverage.

Hornung, however, frames the situation differently. She argues that while these services can genuinely benefit patients, they also allow employers to exercise "utilization management under the guise of lifestyle intervention." The underlying goal, she says, is to eventually move patients off GLP-1 drugs entirely — because employers simply do not want to fund these treatments indefinitely.

## Physicians Raise Alarms Over Patient Safety

For doctors who specialize in obesity medicine, this trend is deeply concerning. Dr. Catherine Varney, obesity medicine director at UVA Health in Charlottesville, Virginia, has watched telehealth companies encourage her patients to discontinue obesity medications — advice she considers both medically inappropriate and potentially harmful.

"They're offering medical advice outside the scope of their practice," she says. "The evidence from clinical trials is clear: when patients stop these medications, they regain approximately two-thirds of their lost weight. It's no different than stopping blood pressure medication and watching your blood pressure climb back up."

### A Real Patient Pays the Price

Penny Byer, a 64-year-old homemaker from Stuarts Draft, Virginia, and mother of five, experienced exactly that outcome. After starting Wegovy in April 2024, she reached a healthy body mass index for the first time in years. Then, Virta Health — another telehealth provider — was added to her family's employee benefits package. By December, Virta had discontinued her prescription.

Within weeks, her weight and cholesterol levels climbed back to where they had been before she ever started the medication.

"Everything's come back with a vengeance," Byer says. Despite weeks of appeals, paperwork, and persistent communication with Virta, the answer never changed. "No matter what I done or papers I brought them — nothing mattered."

Virta Health maintains that its own research supports the idea that patients can sustain weight loss after discontinuing GLP-1 drugs — a position that contradicts findings from larger, broader clinical studies.

## What This Means for Patients Seeking Coverage

The growing influence of employer-hired telehealth companies over GLP-1 prescriptions raises serious questions about where medical decision-making authority truly lies. As obesity drugs become increasingly central to treating not just excess weight but related conditions like sleep apnea, heart disease, and diabetes, the tension between cost containment and patient-centered care is only likely to intensify.

For patients navigating this landscape, the message is sobering: getting a prescription from your doctor may only be the first hurdle in a much longer process.

Employer-hired telehealth firms are limiting patient access to GLP-1 obesity drugs like Wegovy and Zepbound. Here's what patients need to know.

Telehealth Companies Control Access to Obesity Drugs

How Telehealth Companies Are Standing Between Patients and Obesity Medications

The Food and Drug Administration approved a new sunscreen ingredient in the U.S. for the first time in 20 years. It&#039;s been used for decades in Europe and Asia.

A sunscreen ingredient used in Europe and Asia that blocks UVA and UVB rays has been approved for use in the U.S. mihailomilovanovic/iStockphoto/Getty Images hide caption

For the first time in nearly three decades, the Food and Drug Administration approved a new chemical UV filter for use in sunscreens sold in the U.S. And that has many dermatologists cheering.

"This is a very big deal," says Dr. Heather Rogers , a dermatologist in Seattle and a fellow of the American Academy of Dermatology.

Shots - Health News Some TikTok influencers are maligning sunscreen. Here's what to know about the claims The new ingredient is called bemotrizinol, and it has several advantages over the chemical sunscreen ingredients previously available in the U.S., Rogers says.

"It hits like really every box for us that we have been waiting for as dermatologists and consumers," Rogers says.

Here's what you need to know about this new ingredient and how it could lead to better sunscreens sold stateside.

Rogers says in general, you want to use sunscreens that are broad spectrum, meaning they protect against both UVA rays – the longer wavelengths that cause premature aging and wrinkles – and UVB rays, which lead to sunburns. Both types of UV rays can cause skin cancer.

She says the sunscreens currently sold in the U.S. do an excellent job of protecting against UVB rays, but the chemical UV filters available in sunscreens in the U.S. until now aren't as good at blocking out UVA rays.

In general, chemical sunscreens sold in the U.S. rely on an ingredient called avobenzone to block out UVA rays, says Kelly Dobos , a cosmetic chemist who teaches at the University of Cincinnati.

But avobenzone by itself isn't photo stable, meaning its protection can start to break down rapidly when exposed to sunlight. And as avobenzone breaks down, it can release molecules that lead to skin irritation, says Alexa Friedman , a senior scientist with the nonprofit Environmental Working Group, or EWG.

By contrast, bemotrizinol offers protection against both UVA and UVB rays all on its own, and it is photo stable, so it breaks down more slowly, offering better protection, Rogers says.

"So if you go a little longer than two hours to reapply your sunscreen, there will be more protection left," Rogers says. However, she says you should still reapply sunscreen every two hours.

Bemotrizinol has been widely used in European and Asian sunscreens for decades. But it has taken 20 years for the FDA to approve its use in this country.

That's because in the U.S., sunscreens are regulated as over-the-counter drugs rather than cosmetics, as they're classified in Europe. That means ingredients need to undergo rigorous testing for safety and efficacy before they can be approved for use in the U.S.

"It's really expensive and time consuming," Dobos says. The European company DSM-Firmenich spent at least $18 million over more than two decades in its push to gain FDA approval for bemotrizinol.

However, all that testing means bemotrizinol has more safety data to back it up than any other chemical sunscreen ingredient currently approved in the U.S., says Friedman of EWG.

Shots - Health News Picking the 'right' sunscreen isn't as important as avoiding these 6 mistakes "This ingredient is exciting because we have that data to support its safety," Friedman says.

Friedman says animal testing showed bemotrizinol doesn't lead to concerns like reproductive harm, while clinical testing on humans found that it does not irritate the skin, even after repeated application over time, "which is hopefully how people are using sunscreens."

And because bemotrizinol's molecules are larger, it's not readily absorbed by the skin and into the bloodstream, she says.

That's important, because studies have shown that some of the other chemical sunscreen UV filters sold in the U.S. can be absorbed in the bloodstream, prompting calls for more safety data and leading to a backlash against sunscreen on social media fueled by misinformation. Rogers says that trend is concerning because skin cancer is the most common form of cancer.

"We just need to have sunscreen that people will use, that they'll trust," Rogers says. "And this ingredient is going to allow that to happen. And that is very exciting."

And bemotrizinol is also considered to be non-irritating, Friedman says. That should be welcome news to people who've been put off by chemical sunscreens in the past.

Until now, Rogers says, the only sunscreen ingredient available in the U.S. that offered the aforementioned advantages of bemotrizinol – photo stable, non-irritating, minimally absorbed into the skin and with good broad spectrum protection against both UVA and UVB rays – was zinc oxide.

Both zinc oxide and titanium dioxide are mineral UV filters. Both chemical sunscreens and mineral sunscreens work by absorbing UV rays from the sun. Mineral sunscreens also reflect some UV rays. The bigger difference is that mineral sunscreens sit on the surface of the skin, while chemical sunscreens get absorbed into the skin, Rogers says.

Short Wave U.S. sunscreens haven't been updated for decades – but the science has The downside of mineral sunscreens is that they can leave an unattractive white cast on the skin – think of lifeguards with white paste on their noses. "Particularly if you're a person of color, zinc is going to make you look pale, white or ashy, which really makes it hard to use on a regular basis," Rogers says.

Bemotrizinol, on the other hand, is transparent on the skin, and because it protects against both UVA and UVB rays on its own, it doesn't have to be mixed with as many other chemical filters and stabilizers to achieve broad spectrum protection, Dobos adds. She says that should lead to more aesthetically pleasing, less greasy sunscreen formulations in the near future.

"I think it's a real win for public health," Dobos says. "If we can make a sunscreen that consumers like to use and want to use and apply in the proper amounts, I think that's something that's really going to be a win for consumers."

DSM-Firmenich has exclusive rights to market bemotrizinol in the U.S. for 18 months. It will be sold under the brand name Parsol Shield. The company says the first sunscreen products containing the ingredient should start hitting American store shelves around September.

The Food and Drug Administration approved a new sunscreen ingredient in the U.S. for the first time in 20 years. It&#039;s been used for decades in Europe and A

4 things to know about the new sunscreen ingredient the FDA 

4 things to know about the new sunscreen ingredient the FDA approved

## A Crisis Hidden in Plain Sight

Every year, approximately 43,000 women around the world lose their lives to postpartum hemorrhage — excessive bleeding following childbirth. It is the single leading cause of maternal death globally, and yet experts say the vast majority of these deaths are entirely preventable.

A landmark three-part series recently published in *The Lancet* is putting this urgent issue front and center, outlining both the scale of the problem and a clear, evidence-backed roadmap for solving it.

## A Memory That Never Fades

For Dr. Olufemi Oladapo, this issue is deeply personal. Early in his medical career in Nigeria, he watched a woman die of postpartum hemorrhage — a patient who had waited six years to become pregnant. Despite his desperate efforts to secure blood transfusions, he arrived too late.

"I was running around hospitals trying to get blood. By the time I got back, she was gone."

That experience has driven Dr. Oladapo, now a physician with the World Health Organization's Special Programme on Human Reproduction, to co-author this sweeping new research series aimed at preventing similar tragedies.

## The Scale of the Problem

Postpartum hemorrhage affects an estimated 27 million women each year. While some degree of bleeding is a normal part of the birthing process, excessive blood loss can escalate into a life-threatening emergency with alarming speed.

"It can become a medical emergency very quickly," warns Dr. Adam Devall, a professor of maternal health at the University of Oxford. A woman who experienced a completely routine labor can deteriorate within mere minutes if the hemorrhage is not identified and addressed promptly.

Women themselves often recognize the severity instinctively. According to Dr. Ioannis Gallos of the WHO's Maternal and Perinatal Health Unit, patients frequently report feeling as though they are dying — because they are.

"If no one was to act on it, within 10 to 20 minutes, easily a woman can die," he says.

This stark reality is why postpartum hemorrhage is widely described among medical professionals as **a race against time**.

## Simple Solutions That Save Lives

One of the most significant findings from the research series centers on the importance of accurately measuring blood loss. Studies show that visually estimating blood loss — a common practice — misses hemorrhages approximately half the time.

A straightforward solution already exists: a specially designed plastic drape placed beneath the mother during delivery. The drape collects blood into a calibrated pouch, allowing medical staff to quickly and accurately assess the volume of blood lost.

"These lines allow midwives and doctors to easily see the amount of blood loss after the birth," explains Dr. Devall.

Once excessive bleeding is detected, a coordinated set of interventions can be deployed simultaneously, including:

- **Uterine massage** to stimulate contractions
- **Medication** to control bleeding
- **Intravenous fluids** to stabilize the patient

### Evidence From the Field

To test this bundled approach, researchers conducted a large-scale clinical trial spanning Nigeria, Kenya, Tanzania, and South Africa, involving more than 200,000 women. The results were striking — early detection combined with clear treatment protocols produced a **massive decrease in severe bleeding outcomes**.

## A Tale of Two Worlds

Perhaps the most troubling finding in the report is not about the frequency of postpartum hemorrhage, but about survival rates. The condition occurs at roughly equal rates in both wealthy and low-income countries — but the outcomes are dramatically different.

In well-resourced nations like the United States, the mortality rate from postpartum hemorrhage can be **more than 200 times lower** than in under-resourced countries such as Afghanistan, Vietnam, or Nigeria.

"What is different is what is given when these conditions are identified," says Dr. Oladapo.

A key factor in this disparity is access to oxytocin, the primary drug used to control postpartum bleeding. While effective, it requires refrigeration — a significant logistical challenge in regions with unreliable infrastructure.

The researchers also emphasize the need for **simulation-based team training**, comparing it to the kind of coordinated, pit-crew-style rehearsal that emergency medical teams use to respond to crises efficiently and without hesitation.

## A Call to Action — and Reason for Hope

The report has drawn praise from global health leaders. Dr. Harshad Sanghvi, former Chief Medical Officer at Jhpiego — a nonprofit dedicated to women's and children's health — described the series as "a tremendous effort" and "a significant call to action."

Dr. Doreen Kainyu Kaura, a professor of midwifery at the University of the Western Cape in South Africa, echoed this sentiment. Having spent years in delivery rooms across the continent, she sees the research as a validation of what frontline workers already know.

"It will be a fantastic approach to ensure that we have these lifesaving interventions that reach women at the right place, at the right time," she says.

## The Economics of Prevention

Beyond the humanitarian case, there is also a compelling financial argument for action. Dr. Oladapo points out that the current cost of treating postpartum hemorrhage — and bearing the economic consequences of maternal death — far exceeds what prevention would require.

"If you invest even 5% of the cost of postpartum hemorrhage in preventing it, you're going to not just save lives but also save money."

His conclusion is both sobering and hopeful: with existing knowledge and tools, more than **95% of postpartum hemorrhage deaths could be prevented**.

"Women should not be dying from PPH in this day and age, given what we know," he says.

Dr. Sanghvi shares that optimism, suggesting that the elimination of postpartum hemorrhage as the world's leading cause of maternal death is not a distant dream — it is an achievable goal within this very decade.

"I think it is within our reach."

A major Lancet study reveals postpartum hemorrhage kills 43,000 women yearly — and explains how simple tools and training could prevent most deaths.

How to Stop Postpartum Hemorrhage Deaths Worldwide

The Race Against Time: How the World Can End Postpartum Hemorrhage Deaths

## Is Your Skin Care Routine Doing More Harm Than Good?

If your bathroom cabinet looks more like a department store beauty counter than a personal hygiene space, you are not alone. Many people own a dozen or more skin care products, yet only reach for a small handful on a daily basis. The rest sit untouched, collecting dust and quietly draining your wallet.

The modern beauty industry has become extraordinarily skilled at convincing us that flawless skin requires an elaborate arsenal of serums, acids, masks, toners, and creams. Miss a step, the messaging implies, and you are one skipped exfoliant away from premature aging and dull, uneven skin. But is any of that actually true?

## What Healthy Skin Really Means

According to dermatologist and dermatologic surgeon Dr. Michelle Henry, skin care at its most fundamental level is simply about maintaining the health of our outermost layer so it can perform its natural protective functions. Skin does benefit from topical support to help preserve its protective barrier, but that support does not need to come from an overwhelming number of products.

The key is knowing what your skin genuinely needs — and filtering out everything else.

## Setting Realistic Expectations

One of the most important shifts you can make in your skin care journey is adjusting your expectations. Experts emphasize that no cream, serum, or treatment will freeze your skin in time. Aging is a natural process, and the goal of a good skin care routine should be health and comfort — not the pursuit of perpetually youthful skin.

Dr. Henry puts it plainly: "Just because you don't have wrinkle-free, rosy skin does not mean it's not healthy. Healthy skin is comfortable, functional skin. And the good thing is that for the most part, healthy skin does look beautiful."

This perspective is both refreshing and practical. Rather than chasing an impossible standard, focus on keeping your skin functioning well.

## Which Products Are Actually Worth It?

Not every skin concern requires a specialized product. While some conditions — such as hyperpigmentation, significant wrinkling, or loss of skin firmness — may call for targeted treatments, many common issues can be addressed with a streamlined, consistent routine.

Before adding another product to your shelf, consider asking:

- **Does my skin actually need this, or am I responding to marketing?**
- **Am I layering too many active ingredients, which could irritate my skin?**
- **Is this product backed by credible dermatological research?**

A throw-everything-at-it approach is not only costly — it can actively irritate your complexion and compromise the very barrier you are trying to protect.

## Simplify Your Routine, Protect Your Budget

The most effective skin care strategy is an informed one. Understanding the essentials — and resisting the pressure to buy everything marketed to you — can save both money and frustration. Healthy, attractive skin does not require a 10-step routine. It requires the right steps, applied consistently.

Cut through the noise, invest in what works, and give your skin — and your budget — a well-deserved break.

Overwhelmed by skin care choices? Learn which products truly improve skin health and which ones are just marketing noise draining your budget.

Skin Care Products You Actually Need vs. Ones to Skip

Stop Wasting Money on Skin Care Products You Don't Actually Need

## Global HIV Progress Threatened by Funding Crisis and Human Rights Rollbacks

Decades of hard-won progress in the fight against HIV and AIDS now face their most serious threat, according to the United Nations agency leading the global response. A deepening funding crisis, combined with increasingly repressive legislation targeting civil society, is significantly raising the risk of a resurgence in HIV infections and AIDS-related deaths.

Winnie Byanyima, Executive Director of UNAids, described the current situation as "the biggest disruption since the global HIV response was put together," warning that it poses "a major threat to the progress we have had."

## Record Lows Could Soon Be Reversed

A newly released UN report paints a stark picture of the road ahead. While annual HIV infections and AIDS-related deaths currently sit at historic lows — with 1.2 million new infections and 570,000 deaths recorded last year — these gains are increasingly fragile. Without a renewed and coordinated global commitment, experts warn that these numbers could begin climbing again in the near future.

The trigger for this alarming outlook is an unprecedented 23% decline in international aid spending, which has already begun rippling through health systems in the countries most affected by HIV.

## HIV Testing Collapses in High-Burden Countries

One of the most immediate consequences of the funding cuts has been a sharp drop in HIV testing. In 2025, testing rates fell dramatically in nations with the highest rates of infection. Within a single program, tests conducted dropped by 22% compared to the previous year.

"That's huge," Byanyima said. "This means that people don't know that they are HIV positive, continue transmitting the virus, and so the disease will continue to spread and new infections will rise."

Delayed diagnosis also means delayed treatment — a dangerous gap that could prove fatal. "Maybe even more people will die because they don't show for treatment early enough or they don't get on treatment early enough," she added.

## Prevention Services Hit Hardest

Beyond testing, prevention services have taken a particularly severe blow. Programs distributing condoms and providing pre-exposure prophylaxis — medication that protects against HIV infection — have been gutted by the aid cuts.

These services were already chronically underfunded, receiving just 11% of total HIV spending in low- and middle-income countries in 2024. Byanyima noted that even this modest allocation is now disappearing entirely.

New domestic funding from affected governments has not come close to filling the gap, and what funding does exist tends to prioritize treatment over prevention. Byanyima warned that the consequences will be measurable and severe: "rising new infections, and rising numbers of people dying of HIV-related illness" in the years ahead.

## Repressive Laws Silencing Community-Led Health Organizations

Financial pressures are only part of the crisis. Byanyima also pointed to a growing wave of restrictive legislation that is shutting down the community-based organizations most effective at reaching vulnerable populations.

As an example, she cited Uganda's so-called "sovereignty bill," which limits external funding for civil society groups and curtails their ability to operate. Similar measures in other countries are eroding the grassroots networks that have historically served those at highest risk.

The impact has been devastating. A survey of 79 community-led organizations operating across 47 countries revealed an 85% reduction in services for men who have sex with men, and an 82% reduction in services for sex workers — two populations that bear a disproportionate burden of HIV risk. The report concluded bluntly that these organizations "are disappearing."

## A Glimmer of Hope: New Prevention Technology

Despite the grim outlook, Byanyima acknowledged that meaningful opportunities exist. Chief among them is lenacapavir, a groundbreaking injectable HIV prevention drug administered just twice a year. She described it as a "miracle" development in the fight against the virus.

However, she emphasized that such innovations must be deployed at a far greater scale to "bend the curve" on new infections — something that becomes increasingly difficult without adequate funding and operational infrastructure.

## UNAids Itself Faces an Uncertain Future

Ironically, UNAids is not immune to the very crisis it is sounding the alarm about. The agency has been directly impacted by funding cuts driven by the Trump administration's withdrawal of international aid commitments. The UN Secretary General has even proposed that UNAids be wound down entirely by the close of 2025.

Byanyima confirmed that a working group will present restructuring proposals to the UNAids board in October. She envisions the agency continuing in a reduced form — "a much smaller joint programme that is more dispersed within the UN but that continues to have a hub — leading for the UN and for the world."

The question of whether that hub will have the resources and reach to prevent a new HIV epidemic remains urgently and disturbingly open.

UNAids warns that collapsing aid budgets and repressive laws are threatening to reverse decades of HIV progress and spark a dangerous new epidemic.

HIV Epidemic Risk Rises as Funding Cuts Hit Global AIDS Resp

large_4164.jpg

medium_4164.jpg

small_4164.jpg

thumbnail_4164.jpg

4164.jpg

HIV Resurgence Looms as Funding Cuts and Repressive Laws Undermine Global AIDS Response

## A New Era in Prenatal Genetic Testing

Scientists have developed a remarkable maternal blood test capable of identifying thousands of serious genetic conditions in a developing foetus — a breakthrough that could dramatically reduce the need for invasive prenatal screening procedures. Researchers presented the findings at the European Society for Human Genetics conference held in Gothenburg, drawing widespread attention from the global medical community.

## How the Test Works

The technique, called non-invasive foetal sequencing (NIFS), works by detecting minuscule fragments of foetal DNA that naturally circulate within the mother's bloodstream throughout pregnancy. Using highly advanced DNA sequencing technology combined with sophisticated computational analysis, scientists can identify a remarkably broad range of genetic variants across nearly 23,000 genes in the developing foetus — all without touching the baby directly.

Dr. Christopher Whelan, a senior computational scientist at the Broad Institute of MIT and Harvard University, explained the scope of the test's capabilities.

"This test is capable of detecting thousands of serious genetic conditions, including the majority of conditions listed on major newborn sequencing and foetal anomaly panels — such as the 2,500-gene Genomics England foetal anomalies panel," he said.

### Conditions the Test Can Identify

In their validation study, researchers successfully detected a wide array of rare and serious disorders, including:

- **Noonan syndrome**
- **CHARGE syndrome**
- **Stickler syndrome**
- **Achondroplasia**
- **Cystic fibrosis**
- Dozens of additional rare genetic disorders

Many of these conditions, if caught early, can meaningfully influence decisions around pregnancy management, delivery planning, and newborn care.

## A Safer Alternative to Invasive Procedures

Currently, reliable genetic diagnosis during pregnancy typically requires invasive procedures such as amniocentesis or chorionic villus sampling (CVS). While highly effective, both carry small but real risks to the foetus, and many expectant mothers decline them due to fear, cost, access challenges, or stress.

NIFS offers a compelling alternative. In a study involving 565 pregnancies at an average gestational age of 17 weeks, the blood test successfully identified between 95% and 99% of all genetic variants detected by invasive methods, and captured more than 97% of clinically significant variants.

"We envision this as a frontline test for cases where the foetus has presented with an anomaly during an ultrasound or other screening," said Dr. Whelan. "It gives clinicians a powerful diagnostic tool without putting mothers or babies through an invasive procedure."

## Expert Reactions: Excitement and Caution

The scientific community has largely welcomed the development, though some experts urge careful consideration of how broadly the test should be applied.

Professor Alexandre Reymond of the University of Lausanne called the achievement extraordinary. "Sequencing the entire genome of a foetus without obtaining a direct sample is a tour de force. It immediately unlocks new treatment and prevention possibilities and will change reproductive medicine permanently."

Professor Angus Clarke, a clinical geneticist at Cardiff University, praised the technical achievement but sounded a note of caution regarding widespread screening use. He warned that applying the test broadly — beyond cases where a specific condition is already suspected — risks uncovering genetic variants of unknown clinical significance, potentially triggering unnecessary anxiety for parents and leading babies down a path of unwarranted medical surveillance.

"When you don't have a specific problem you're seeking answers for, simply producing potential answers can create more problems than it solves," Clarke cautioned. "You're placing parents in an incredibly difficult position."

## What This Means for the Future of Prenatal Care

Non-invasive prenatal testing based on foetal DNA has already transformed pregnancy diagnostics — most notably in screening for chromosomal conditions like Down's syndrome. However, NIFS represents a dramatic leap forward, potentially expanding non-invasive screening to cover virtually the full spectrum of conditions currently monitored through newborn genetic panels.

If further clinical validation confirms its reliability and safety, NIFS could become a standard diagnostic tool in prenatal care, offering families earlier, safer, and more comprehensive genetic insights than ever before — while reshaping how medicine approaches pregnancy from the very beginning.

A new maternal blood test called NIFS can detect thousands of genetic conditions in unborn babies, offering a safer alternative to invasive prenatal procedures.

Blood Test Detects Thousands of Genetic Conditions in Pregna

large_4800.jpg

medium_4800.jpg

small_4800.jpg

thumbnail_4800.jpg

4800.jpg

Revolutionary Blood Test Could Detect Thousands of Genetic Conditions Before Birth

## NHS Corridor Care Crisis: Nearly 3,000 Patients Treated in Unsafe Conditions Every Day

Groundbreaking data published for the first time has laid bare the staggering extent of so-called corridor care across NHS hospitals in England, revealing that close to 3,000 patients per day are being treated in wholly inappropriate makeshift settings — a situation government ministers have condemned as both unsafe and completely unacceptable.

### What the New Data Reveals

The figures, covering the month of May, show that an average of 2,241 patients each day experienced corridor care while being treated in Accident and Emergency departments, with an additional 669 patients per day facing the same conditions on or near hospital wards. Combined, this represents approximately 3 to 4 percent of all patients entering hospital through A&E on any given day.

Corridor care is formally defined as any situation in which a patient spends more than 45 minutes receiving treatment in an unsuitable environment. While corridors are the most commonly cited setting, patients have also been treated in side rooms and, in some cases, car parks.

NHS analysis further highlighted that just 20 hospital trusts were responsible for more than half of all A&E corridor care cases, while another group of 20 trusts accounted for over two-thirds of similar incidents occurring elsewhere within their hospitals.

### Real Patients, Real Consequences

Beyond the statistics lie deeply troubling personal accounts from patients and their families.

Suzanne, whose elderly mother — a woman in her eighties — was taken to an A&E department in the East Midlands on five separate occasions this year, described each visit as harrowing. Every admission resulted in her mother waiting more than 24 hours on a trolley in a corridor, surrounded by other patients in identical circumstances.

"Mum was one trolley in a sea of trolleys," Suzanne recalled. Confused, distressed, and vulnerable, her mother only received basic care — help reaching the toilet or a simple drink of water — because family members were present to advocate for her. "If we hadn't been, I dread to think what might have happened," she said.

Another patient, Kathy, was referred by her GP to a hospital in the East of England after presenting with a suspected eye infection. She spent 36 hours sitting alone in a chair before finally being informed that her deteriorating vision was, in fact, caused by a brain tumour. "It was horrendous," she said. "I got home and threw up. I was exhausted and broken."

### Nursing Staff Pushed to the Breaking Point

Frontline nursing staff, speaking anonymously, painted an equally disturbing picture of conditions on the ground.

One nurse recounted a shift during which a deceased patient had to be wheeled past a corridor full of vulnerable, conscious patients on the way to the mortuary. Shortly afterward, another patient suffered a cardiac arrest in the same corridor, with frail and frightened onlookers forced to witness emergency resuscitation attempts being carried out mere feet away. "There's no dignity in that," the nurse said.

In perhaps the most harrowing account, another nurse described a patient who passed away in a hospital corridor without anyone noticing — remaining there long enough that staff only discovered the death after rigor mortis had begun to set in. "It's horrific to think someone's loved one died with no one near them," she said.

### Government Pledges and Political Pressure

Health Secretary James Murray has publicly committed to eliminating corridor care entirely by 2029, describing the practice as having "no place in our NHS." The decision to publish this data for the first time was framed as an effort to hold underperforming trusts accountable and direct support to where it is most urgently needed.

NHS England noted that while May is not traditionally one of the most pressurised months for hospitals, an unseasonable heatwave contributed to unusually high demand throughout the period.

### Healthcare Leaders Sound the Alarm

Professional bodies and independent health analysts have responded to the figures with grave concern. Professor Nicola Ranger, General Secretary of the Royal College of Nursing, described the data as "alarming" and stressed that the crisis extends beyond patients to the nursing workforce itself, with staff becoming increasingly demoralised by being compelled to deliver substandard care on a daily basis.

Siva Anandaciva of The King's Fund think tank welcomed the publication of the data as a positive development, but cautioned against complacency. "We have had data on long waits in other parts of the NHS for decades — including A&E departments — and it has done little to stop their rise," he warned, adding that the figures confirm the scale of a practice that should never have been allowed to become normalised within Britain's health service.

New NHS data reveals nearly 3,000 patients daily are treated in unsafe corridor settings across England, prompting government pledges to end the practice by 202

NHS Corridor Care Crisis: 3,000 Patients a Day in England

31d52750-6583-11f1-8546-8f19e4fe30f4.jpg

Almost 3,000 NHS Patients Daily Forced Into Corridor Care Across England

Katie Tinkler was one of the patients whose severe lupus went into remission after NHS trial of CAR T-cell therapy at University College London hospital. Photograph: Lucy North/PA View image in fullscreen Katie Tinkler was one of the patients whose severe lupus went into remission after NHS trial of CAR T-cell therapy at University College London hospital. Photograph: Lucy North/PA Lupus patients in England in remission after pioneering NHS trial of GM therapy Doctors say therapy that genetically modifies person’s T-cells could offer cure for chronic autoimmune disease

Five lupus patients in England are in remission after being treated with a revolutionary therapy that genetically modifies their own cells, in a medical breakthrough that could offer people a cure, doctors have said.

CAR (chimeric antigen receptor) T-cell therapy involves removing a type of white blood cell also called T lymphocytes, which are crucial for hunting out infected or damaged cells, and engineering them to spot and destroy disease. The T-cells are then fed back into the patient via an infusion to reset their immune system.

The therapy is already revolutionising cancer treatment. Now medics in London have successfully used the technique to effectively cure five NHS patients with severe lupus aged between 19 and 50.

CAR T-cell therapy, which patients only need to have once, could transform lupus treatment and remove the need for lifelong medication, doctors said.

One of the five patients said she no longer had any of the main symptoms of the disease more than three decades after her diagnosis. Katie Tinkler has also skied for the first time in a decade and was able to dance at her daughter’s wedding.

In an NHS trial led by University College London hospitals foundation trust (UCLH) and University College London (UCL), nine patients with severe lupus were recruited. They had not previously responded to any treatments. Most had lupus nephritis, a serious complication involving the kidneys.

Six patients received a lower dose of CAR-T and three got a higher dose. Five of those on the lower dose, who were followed up for an average of 11 months, went into remission within just a few months.

The three on the higher dose have only been followed up for three months so far, but doctors believe they too could achieve remission.

Tests showed patients experienced rapid improvements in markers of the disease, including a stabilisation or improvement in their kidney function, which had been damaged by lupus.

Lupus is a chronic autoimmune disease in which the immune system attacks healthy tissues, causing widespread inflammation and damage to organs such as the kidneys, lungs and heart.

It can range from mild to severe, with symptoms including joint pain, skin problems, fatigue and inflammation of major organs. About 5 million people worldwide are thought to have lupus, which mostly affects women.

Prof Karl Peggs, the director of UCLH’s biomedical research centre, said that while larger studies were needed, CAR T-cell therapy could offer people the chance of a cure. “These findings are truly groundbreaking and offer fresh hope to people living with lupus,” he said.

“While more research is needed, the possibility that CAR T-cell therapy could deliver an immune reset and potentially free patients from the cycle of chronic autoimmune disease marks a remarkable step forward.

“If these results are confirmed in larger studies, the prospect of a cure for lupus may no longer be out of reach.”

Tinkler had to give up her job as a fitness instructor because of pain and fatigue caused by the severe lupus she had had since she was 20.

Lupus caused her to develop swollen and painful joints, kidney damage, lung and heart disease, and a tendency to develop blood clots. Tinkler also experienced sepsis and multi-organ failure, and had to be put in a coma in intensive care.

Now the 52-year-old from Guildford, Surrey, who is married and has three adult children, is in remission. “Thinking about how life was for beforehand and how it is now, it’s like night and day,” she said.

“My whole system was affected by lupus and my joints were so painful that sometimes I couldn’t walk. I couldn’t use my hands to pick up mugs.

“My kidneys, heart and lungs were all getting worse. But now I don’t have these problems any more. It’s miraculous for me. My life two years ago versus now, it’s unrecognisable. I feel blessed.”

Doctors say therapy that genetically modifies person’s T-cells could offer cure for chronic autoimmune disease